Evaluation of a newly proposed renal risk score for Japanese patients with ANCA-associated glomerulonephritis

Clin Exp Nephrol. 2022 Aug;26(8):760-769. doi: 10.1007/s10157-022-02217-w. Epub 2022 Apr 8.

Abstract

Background: We determined the usefulness and prognostic ability of the renal risk score (RRS), proposed in Europe, for Japanese patients with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN) and high myeloperoxidase (MPO)-ANCA positivity; these aspects remain to be verified.

Methods: This retrospective study was conducted on 86 Japanese patients with new, biopsy-confirmed AAGN. We calculated the RRS and analyzed the relationship between this classification, and clinicopathological features and prognosis. We also compared the predictive values between RRS for endpoints including renal death and conventional prognostic tools for patients with AAGN.

Results: There were 33, 37, and 16 patients in the low-, medium-, and high-risk groups, respectively. All patients were MPO-ANCA positive. The median follow-up period was 33 months; 16 (18.6%) patients progressed to end-stage renal disease (ESRD). In the high-risk group, 9/16 (56.3%) patients progressed to ESRD, and renal prognosis was significantly poorer than that in other groups (low-risk group, P < 0.001; medium-risk group, P = 0.004). In Cox multivariate regression analysis, RRS was an independent, poor renal prognostic factor (hazard ratio 5.22; 95% confidence interval 2.20-12.40; P < 0.001). The receiver-operating characteristic curves of the RRS for each endpoint were comparable with those of the 2010 histological classification and those of the severity classification of Japanese rapidly progressive glomerulonephritis.

Conclusions: This is the first study to report the usefulness of the RRS for predicting renal outcomes among Japanese patients with AAGN. Our predictive value of the RRS was comparable with that of conventional prognostic tools.

Keywords: Antineutrophil cytoplasmic antibody-associated glomerulonephritis; Japanese cohort; Prognosis; Renal risk score; Validation study.

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / complications
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / diagnosis
  • Antibodies, Antineutrophil Cytoplasmic
  • Glomerulonephritis* / pathology
  • Humans
  • Japan / epidemiology
  • Kidney Failure, Chronic* / diagnosis
  • Kidney Failure, Chronic* / etiology
  • Prognosis
  • Retrospective Studies
  • Risk Factors

Substances

  • Antibodies, Antineutrophil Cytoplasmic